ANNX Annexon, Inc.

NASDAQ
$3.10

Annexon, Inc. (ANNX) is expected to report earnings on February 8, 2027, before the market open. The consensus earnings estimate is a loss of $0.25 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -27.9% since its last earnings release on November 9, 2026.

Annexon Beat Consensus Estimates
Monday, November 9, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 6:05 AM ET
Earnings Whisper
-
vs ($0.25)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.71

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Annexon, Inc.

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.